Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02826460 · ClinicalTrials.gov registry record

Psychosocial Risks in Liver Transplant Recipients

A clinical trial of End Stage Liver DIsease, sponsored by Icahn School of Medicine at Mount Sinai.

Completed
Registry status
200
Enrollment target
1
Study location

NCT02826460: Completed study of End Stage Liver DIsease, sponsored by Icahn School of Medicine at Mount Sinai.

NCT02826460 is a study of End Stage Liver DIsease that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 200 participants, below the 479-participant average among 16 other End Stage Liver DIsease trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02826460, a study of End Stage Liver DIsease, has completed, sponsored by Icahn School of Medicine at Mount Sinai.

COMPLETED
Registry status
200 participants
Enrollment target
1
Study location

Study Summary

A retrospective chart review in which the information in the standard psychosocial evaluations done pre-transplant for liver transplant recipients will be coded, recorded, and correlated with posttransplant outcomes of the same recipients. Evaluated outcomes include rejection episodes and adherence to tacrolimus, calculated through the MLVI (Medication Level Variability Index). The researchers will evaluate the degree to which both single elements in the evaluation as well as a cumulative score derived by a structured review of the chart using the Stanford Integrated Psychosocial Assessment for Transplantation (SIPAT) model can predict posttransplant outcomes.

Primary Outcome

Number of Rejections confirmed by biopsy

Conditions Studied

End Stage Liver DIsease

Study Locations (1)

New York

  • Icahn School of Medicine at Mount Sinia - New York

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2014-11
Est. Completion 2016-06
Icahn School of Medicine at Mount Sinai

708 total trials

What the finished NCT02826460 record still lists

NCT02826460 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 479-participant average among 16 other End Stage Liver DIsease trials with a reported enrollment target (58% lower).

The record links to 1 condition, with End Stage Liver DIsease appearing as the primary indexed condition, and to 0 interventions.

NCT02826460 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT02826460 about?

NCT02826460 is a clinical study titled "Psychosocial Risks in Liver Transplant Recipients". A retrospective chart review in which the information in the standard psychosocial evaluations done pre-transplant for liver transplant recipients will be coded, recorded, and correlated with posttransplant outcomes of the same recipients. Evaluated outcomes include rejection episodes and adherence ...

What is the current status of trial NCT02826460?

This trial is currently completed. The enrollment target is 200 participants. The study started on 2014-11. Estimated completion is 2016-06.

What conditions does trial NCT02826460 study?

This clinical trial studies the following conditions: End Stage Liver DIsease.

Who is sponsoring clinical trial NCT02826460?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02826460 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for End Stage Liver DIsease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02826460's enrollment target sits among peer trials

200 6th of 16 higher than 10 of 16 other End Stage Liver DIsease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other End Stage Liver DIsease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00107289 · 200 participants · Phase 2

    Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

  • NCT00109174 · 200 participants · NA

    MRS Measurement of Glutamate and GABA Metabolism in Brain

  • NCT00177268 · 200 participants

    Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

  • NCT00493688 · 200 participants

    A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT02826460, the US trial registry maintained by the National Library of Medicine. NCT02826460 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.